» Articles » PMID: 33229895

Factors Associated with Worse Cerebrovascular Function in Aging Women with and at Risk for HIV

Overview
Journal AIDS
Date 2020 Nov 24
PMID 33229895
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Women may be disproportionately impacted by the negative effect of HIV on cerebrovascular risk. We examined the association of HIV, sex, menopause, and immune activation with cerebrovascular function among women with HIV (WWH) and at risk for HIV from the Women's Interagency HIV Study and men with HIV.

Design: Cross-sectional.

Methods: Participants were aged at least 40 years with coronary heart disease or at least one cardiometabolic risk factor. All persons with HIV were on antiretroviral therapy with undetectable viral load. Cerebral vasoreactivity was assessed by the transcranial Doppler breath-holding test, with lower vasoreactivity corresponding to worse cerebrovascular function. Menopausal status was determined by anti-Müllerian hormone level. We used mixed effects linear regression to identify factors associated with cerebral vasoreactivity.

Results: Mean cerebral vasoreactivity was similar in WWH (n = 33) and women at risk for HIV (n = 16). A trend toward higher cerebral vasoreactivity in WWH compared with men with HIV (n = 37) was no longer present after excluding women on estrogen replacement therapy (n = 3). In women, menopausal status was not significantly associated with cerebral vasoreactivity. WWH with higher cardiovascular risk (-0.14 for each additional cardiometabolic risk factor, P = 0.038), sCD163 (-0.20 per doubling, P = 0.033), and proportion of CD4+CX3CR1+ T cells (-0.14 per doubling, P = 0.028) had lower cerebral vasoreactivity.

Conclusion: Among older women at high cardiovascular risk, women with virologically suppressed HIV and women at risk for HIV had similar cerebrovascular function. Our findings, which must be interpreted in the context of the small sample, highlight the contribution of traditional cardiometabolic risk factors and immune activation to cerebrovascular risk in WWH.

Citing Articles

Cocaine use is associated with cerebral white matter hyperintensities in HIV disease.

Meade C, Bell R, Towe S, Lascola C, Al-Khalil K, Gibson M Ann Clin Transl Neurol. 2023; 10(9):1633-1646.

PMID: 37475160 PMC: 10502656. DOI: 10.1002/acn3.51854.


Long COVID in people living with HIV.

Peluso M, Antar A Curr Opin HIV AIDS. 2023; 18(3):126-134.

PMID: 37144614 PMC: 10167544. DOI: 10.1097/COH.0000000000000789.


Central Nervous System Effects of COVID-19 in People with HIV Infection.

Peluso M, Hellmuth J, Chow F Curr HIV/AIDS Rep. 2021; 18(6):538-548.

PMID: 34843065 PMC: 8628487. DOI: 10.1007/s11904-021-00582-x.

References
1.
Nelson S, Pastuszek E, Kloss G, Malinowska I, Liss J, Lukaszuk A . Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. Fertil Steril. 2015; 104(4):1016-1021.e6. DOI: 10.1016/j.fertnstert.2015.06.024. View

2.
Borges A, OConnor J, Phillips A, Neaton J, Grund B, Neuhaus J . Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis. 2016; 214(3):408-16. PMC: 4936649. DOI: 10.1093/infdis/jiw173. View

3.
Harlow S, Gass M, Hall J, Lobo R, Maki P, Rebar R . Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012; 97(4):1159-68. PMC: 3319184. DOI: 10.1210/jc.2011-3362. View

4.
Callen A, Dupont S, Pyne J, Talbott J, Tien P, Calabrese E . The regional pattern of abnormal cerebrovascular reactivity in HIV-infected, virally suppressed women. J Neurovirol. 2020; 26(5):734-742. PMC: 7895531. DOI: 10.1007/s13365-020-00859-8. View

5.
Funderburg N, Zidar D, Shive C, Lioi A, Mudd J, Musselwhite L . Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012; 120(23):4599-608. PMC: 3512236. DOI: 10.1182/blood-2012-05-433946. View